Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Recipients of any race, 18 years or older
Recipients of primary de novo orthotopic liver transplant from a deceased donor
Recipients of a kidney with a cold ischemia time \< 30 hours
HCV-negative recipients
You may not be if
Prior organ/cellular transplant or multiple organ transplant
MELD-score \> 35
HCC \> Milan criteria
Donor age \< 12 years
Cold ischemia \> 15 hours
Patients who are treated with drugs that are strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4) or drugs with QT-prolonging properties
Clareo Health | Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients
